Baseline Productions, Inc. (BSSP) Stock

About Baseline Productions, Inc.

As of 2021, Baseline Productions, Inc. is actively pursuing opportunities for a merger or acquisition. Simultaneously, the company is working to bring its operations and status up-to-date. This strategic shift follows a significant development on October 9, 2017, when its Pharmaceutical Services Agreement (PSA) with Canteck Pharma, Inc. was terminated. The reason for this termination was the company's inability to secure the necessary licensing to proceed with its immunotherapeutic-based technology, which was specifically targeted at cancer indications, within Mexico.

Baseline Productions, Inc. (BSSP) stock trades at $0.00 with a market capitalization of $74377. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of -0.02, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Baseline Productions, Inc. generates a return on equity (ROE) of 166.21% — well above the market average, a sign of a high-quality business, return on capital employed of 57.82%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.cantechpharma.com